Hologic had unveiled plans to acquire Biotheranostics for $230 million in January. Through the deal, Hologic gains two laboratory-developed tests -- the Breast Cancer Index, which predicts effects of endocrine therapy in breast cancer patients and CancerType ID, which aids in the molecular characterization of uncertain and unknown cancers.